| TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients (NCT07489755) | Shenzhen TargetRx Co., Ltd. | 2026-04-01 |
| TGRX-678 Pharmacokinetic Mass Balance (NCT06986772) | Shenzhen TargetRx Co., Ltd. | 2025-07-07 |
| TGRX-678 Phase I Oral Pharmacokinetic Study (NCT06697899) | Shenzhen TargetRx Co., Ltd. | 2024-11-24 |
| TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients (NCT06453902) | Shenzhen TargetRx Co., Ltd. | 2024-07-15 |
| TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies (NCT06484816) | Shenzhen TargetRx Co., Ltd. | 2024-07-08 |
| TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia (NCT06088888) | Shenzhen TargetRx Co., Ltd. | 2024-07-02 |
| TGRX-326 Pharmacokinetic Mass Balance (NCT06438367) | Shenzhen TargetRx Co., Ltd. | 2024-06-26 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies (NCT06206174) | Shenzhen TargetRx Co., Ltd. | 2024-03-06 |
| TGRX-326 Pharmacokinetic Drug Interaction (NCT06294561) | Shenzhen TargetRx Co., Ltd. | 2024-03-04 |
| TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) (NCT06082635) | Shenzhen TargetRx Co., Ltd. | 2023-12-14 |
| TGRX-326 Pharmacokinetic Food Effect Bioavailability Study (NCT06304805) | Shenzhen TargetRx Co., Ltd. | 2023-12-13 |
| TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) (NCT05955391) | Shenzhen TargetRx Co., Ltd. | 2023-01-18 |
| TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) (NCT05441956) | Shenzhen TargetRx Co., Ltd. | 2021-04-23 |
| TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients (NCT05434312) | Shenzhen TargetRx Co., Ltd. | 2021-03-29 |